Abstract
S917 Mirikizumab Achieved Comprehensive Disease Control in Patients With Ulcerative Colitis From Phase 3 LUCENT-1 and LUCENT-2 Trials
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
